KR20220120625A - 지방족 산 아미드 유도체 - Google Patents

지방족 산 아미드 유도체 Download PDF

Info

Publication number
KR20220120625A
KR20220120625A KR1020227025336A KR20227025336A KR20220120625A KR 20220120625 A KR20220120625 A KR 20220120625A KR 1020227025336 A KR1020227025336 A KR 1020227025336A KR 20227025336 A KR20227025336 A KR 20227025336A KR 20220120625 A KR20220120625 A KR 20220120625A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
pharmaceutically acceptable
acceptable salt
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227025336A
Other languages
English (en)
Korean (ko)
Inventor
유키 후지이
마사유키 사쿠마
요시노리 아이하라
제레미 베스너드
앤드류 사이먼 벨
Original Assignee
스미토모 파마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미토모 파마 가부시키가이샤 filed Critical 스미토모 파마 가부시키가이샤
Publication of KR20220120625A publication Critical patent/KR20220120625A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020227025336A 2019-12-24 2020-12-23 지방족 산 아미드 유도체 Pending KR20220120625A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019232927 2019-12-24
JPJP-P-2019-232927 2019-12-24
PCT/JP2020/048117 WO2021132311A1 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Publications (1)

Publication Number Publication Date
KR20220120625A true KR20220120625A (ko) 2022-08-30

Family

ID=76574184

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025336A Pending KR20220120625A (ko) 2019-12-24 2020-12-23 지방족 산 아미드 유도체

Country Status (14)

Country Link
US (3) US12503463B2 (https=)
EP (1) EP4082616B1 (https=)
JP (1) JP7662534B2 (https=)
KR (1) KR20220120625A (https=)
CN (1) CN114981264B (https=)
AU (1) AU2020413284A1 (https=)
BR (1) BR112022011844A2 (https=)
CA (1) CA3161806A1 (https=)
ES (1) ES3040677T3 (https=)
HU (1) HUE072877T2 (https=)
MX (1) MX2022007947A (https=)
PL (1) PL4082616T3 (https=)
PT (1) PT4082616T (https=)
WO (1) WO2021132311A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880930A (en) 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
EP0732332B1 (en) 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用
FR2827287B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2006508101A (ja) 2002-11-08 2006-03-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー フェニルアルキルおよびピリジルアルキルピペラジン誘導体
AU2006239302B2 (en) 2005-04-26 2011-07-07 Hypnion, Inc. Benzisoxazole piperazine compounds and methods of use thereof
PL392436A1 (pl) 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
WO2014079155A1 (zh) * 2012-11-26 2014-05-30 辽宁贝雷生物制药有限公司 苯并五元氮杂环基哌嗪或哌啶衍生物的用途
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Bonaventure P, J Pharmacol Exp Ther. 321: 690-8, 2007
C. J. Schmidt, Life Science. 56(25): 2209-2222, 1995
C. Sanchez, Pharmacology & Therapeutics. 145: 43-57, 2015
Horisawa T, Behavioural Brain Research. 220: 83-90, 2011
L. Citrome, J. Clinical Practice. 65(2): 189-210, 2011
M. Guscott, Neuropharmacology. 48: 492-502, 2005
P. Seeman, Can. J. Psychiatry. 4: 27-38, 2002
T W. Lovenberg, Neuron. 11: 449-458, 1993
YS. Woo, Neuropsychiatric Disease and Treatment. 9: 1521-1529, 2013

Also Published As

Publication number Publication date
US12503463B2 (en) 2025-12-23
TW202136235A (zh) 2021-10-01
CA3161806A1 (en) 2021-07-01
EP4082616A1 (en) 2022-11-02
US20220073506A1 (en) 2022-03-10
US20260078115A1 (en) 2026-03-19
JPWO2021132311A1 (https=) 2021-07-01
BR112022011844A2 (pt) 2022-08-30
WO2021132311A1 (ja) 2021-07-01
EP4082616B1 (en) 2025-09-03
US11339151B2 (en) 2022-05-24
JP7662534B2 (ja) 2025-04-15
CN114981264A (zh) 2022-08-30
PL4082616T3 (pl) 2025-12-15
MX2022007947A (es) 2022-07-27
EP4082616A4 (en) 2024-01-03
AU2020413284A1 (en) 2022-08-18
US20220213079A1 (en) 2022-07-07
PT4082616T (pt) 2025-12-02
HUE072877T2 (hu) 2025-12-28
CN114981264B (zh) 2024-07-26
ES3040677T3 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
TW202134229A (zh) 環烷基尿素衍生物
US20260078115A1 (en) Aliphatic acid amide derivative
AU2013291617B2 (en) Carbamate/urea derivatives
CN117561238A (zh) 苯基脲衍生物
CA3103932A1 (en) Pyridinyl pyrazoles as modulators of roryt
JP7097342B2 (ja) ２，６－ジ置換ピリジン誘導体
JP2020023570A6 (ja) ２，６−ジ置換ピリジン誘導体
JP7655885B2 (ja) 脂肪族酸アミド誘導体を含有する医薬組成物
TWI917344B (zh) 脂肪族酸醯胺衍生物
HK40079616B (en) Aliphatic acid amide derivative
HK40079616A (en) Aliphatic acid amide derivative
CA3199269A1 (en) Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EA046822B1 (ru) Производное амида алифатической кислоты
BR112017005241B1 (pt) Composto, composição farmacêutica, e, uso de um composto
JP7382188B2 (ja) ２，６－ジ置換ピリジン誘導体からなる医薬
JP7713954B2 (ja) 核内受容体に対して活性な化合物
JP2025526368A (ja) Ｉｒａｋ３のリガンド指向性分解分子としての置換ピラゾリル－ピリジニル化合物
HK40017726A (en) 2,6-disubstituted pyridine derivative

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000